Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex in Pre-menopausal Women With Symptomatic Leiomyomata
NCT00882258Phase 2Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Mar 2006
- Primary completion
- Mar 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telapristone in Uterine Fibroids (UF) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: To evaluate Proellex administered once daily in pre-menopausal women with symptomatic leiomyomata at 91 days. Started Mar 2006; status: completed.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT00882258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882258.